IMAC Holdings, Inc. announced it has initiated the third and final cohort of its Phase I clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson’s disease.
[IMAC Holdings, Inc. (]
Sorry, but the selected Zotpress account can't be found.
